



Iceland

Icelandic Medicine Pricing and Reimbursement Committee
Telephone: +354 553 9000 e-mail: verd@lgn.is

Pharmaceutical system in Iceland in the in- and out-patient sector

New medicine

AUTHORISATION/
CLASSIFICATION

European Medicines Agency (EMA) or The Icelandic Medicine Agency (IMA)

Task: Decision on authorization and registration
Criteria: Quality, safety, efficacy (Directive 2004/27/EC) and Icelandic Medicines Act

The Icelandic Medicine Agency (IMA) is an independent regulatory authority that appertains to the Ministry of Health.

in consultation with

The Pharmaceutical Committee

Task: Decision on prescription, dispensing requirements and if a medicine fulfills the criteria of medicines
Criteria: Directive 92/56/EEC, Icelandic Medicines Act, prescription ordinance etc.

The Icelandic Medicine Agency (IMA), is also in charge of pharmacovigilance.

VIGILANCE

PRICING
wholesale level

Icelandic Medicine Pricing and Reimbursement Committee (IMPRC)

Task: Calculation of Nordic average price for general medicines
Criteria: External price referencing

Price approval for all prescription drugs and hospital drugs.
OTC is free price.

Task: Calculation of Nordic lowest price for hospital/high cost medicines
Criteria: External price referencing

PRICING
Pharmacy level

Wholesaler Free mark up at Wholesale level

University Hospital

Pharmacies Maximum mark up set by the **Icelandic Medicine Pricing and Reimbursement Committee** (2 different steps: one for a 11% plus 5,86 € fixed fee and the second step 2% with 13,86 € fixed fee (depending on Wholesale price).

Tenders or Negotiated Procedure regarding medications, for all hospitals in Iceland are organized by the University Hospital

Task: Price negotiations or tendering of medicines
Criteria: Depending on the product or on the market situation of the medicine

VAT: 24%

REIMBURSEMENT

General reimbursement

Icelandic Medicine Pricing and Reimbursement Committee (IMPRC)

Task: Decision on the reimbursement status
Criteria: Reimbursement in the Nordics, Price is relative to efficacy and in comparisons to already reimbursed drugs, Budget impact

National Reimbursement Code set by the Ministry of Health paid by the National Insurance.

Fully reimbursed – no copayment by patient
Some medicines for patient who are terminally ill, patients with kidney problems and for patient with psychiatric problems

Co-payment system
Co-payment is a proportion of the annual usage
Step-wise increase in co-payment by the Health Insurance up-to a full reimbursement

Individual reimbursement

Reimbursement on individual application possible
Non reimbursable medicines and medicines not applied for inclusion in the Reimbursement Code.

Icelandic Medicine Pricing and Reimbursement Committee (IMPRC) in cons. with **University Hospital and Health Insurance**

Task: Decision on reimbursement status of hospital/high cost medicines
Criteria: Price relative to efficacy
Budget impact
Clinical evaluation done by the University Hospital
Clinical guidelines done by the University Hospital
Evaluations within fixed budget done by the Health Insurance

Fully reimbursed – no copayment by patient
Hospital and some high cost medicines

Use in hospitals

Regional Hospitals in cons. with **Pharmaceutical and Therapeutic Committee per hospital**

Task: Decision on use of medicines
No co-payment for patients

Pharmaceutical formulary per hospital